383930.KQ DT&CRO Co. Ltd.
- Market cap
- KRW 23.5B
- P/E
- -
- P/B
- 3.26x
- ROE
- -496.1%
- Dividend yield
- -
- Fundamental score
- 0.4/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 383930.KQ undervalued?
Graham numberThe Graham number of DT&CRO Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DT&CRO Co. Ltd. fundamental analysis
2 of 21 checks passedROE 0/2
Low return on equity (-496.1%), below 10%.
ROA 0/1
Return on assets (-39.6%) is below the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-38.8%) is below the industry median (4.8%).
Revenue Growth 1/2
Revenue grew 2.8% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (157.4%), above 100%.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Cash Runway 0/2
Cash covers 0.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (3.3x) is above the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
DT&CRO Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DT&CRO Co. Ltd.
DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional food, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin-si, South Korea.
Full company profileDT&CRO Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DT&CRO Co. Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 32.7B | 44.0B | 26.6B | 36.0B | 47.7B | 42.8B |
| Gross Profit | 7.54B | 8.98B | -6.72B | -3.10B | 2.61B | -3.34B |
| Operating Income | 4.91B | 5.29B | -13.2B | -11.3B | -5.74B | -20.3B |
| EBITDA | - | 8.62B | -12.1B | 4.94B | 6.13B | -25.4B |
| Net Income | 4.33B | 5.26B | -16.6B | -2.00B | -2.78B | -35.8B |
| EPS | 345 | 416 | -1,307 | -157 | -217 | -2,797 |
| Balance Sheet | ||||||
| Total Assets | 32.9B | 64.5B | 59.8B | 81.1B | 90.4B | 90.3B |
| Total Liabilities | 14.9B | 18.2B | 28.2B | 52.4B | 65.3B | 83.1B |
| Shareholders' Equity | 18.0B | 46.3B | 31.7B | 28.7B | 25.1B | 7.21B |
| Cash & Short-term Investments | 7.07B | 20.5B | 5.05B | 4.67B | 335M | 1.57B |
| Cash Flow | ||||||
| Operating Cash Flow | 6.06B | 5.01B | -3.52B | -6.40B | -2.26B | -3.56B |
| Capital Expenditure | 8.05B | 14.9B | 17.1B | 19.3B | 11.9B | 4.21B |
| Free Cash Flow | -2.00B | -9.86B | -20.6B | -25.7B | -14.2B | -7.77B |
| Ratios | ||||||
| ROE | 24.0% | 11.3% | -52.5% | -7.0% | -11.1% | -496.1% |
| ROA | 13.2% | 8.1% | -27.8% | -2.5% | -3.1% | -39.6% |
| Net Profit Margin | 13.2% | 11.9% | -62.6% | -5.6% | -5.8% | -83.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
DT&CRO Co. Ltd. dividends
DT&CRO Co. Ltd. has not paid dividends in the last 5 fiscal years.
Last stock split: 2:1 on Mar 9, 2023.
Who owns DT&CRO Co. Ltd.
- Insiders 30.74%
- Institutions 0.00%
- Public & others 69.26%
- Shares outstanding 12.8M
- Free float 8.85M
DT&CRO Co. Ltd. company profile
- Company name
- DT&CRO Co. Ltd.
- Ticker
- 383930.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 28, Baengnyeong-ro 20beon-gil, Yongin-si, South Korea, 17042
- Phone
- 82 3 1322 2400
- Website
- dtncro.com
About DT&CRO Co. Ltd.
DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional food, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin-si, South Korea.